IGF1R and non-small cell lung carcinoma: In a recent randomized phase II trial involving patients with stage IIIB, IV, or recurrent, treatment-naïve NSCLC, addition of an anti-IGF-1R antibody (CP-751,871; Pfizer) to standard chemotherapy (paclitaxel and carboplatin) led to a 46% objective response rate versus a 32% rate in patients receiving chemotherapy alone [12].